{"id":"placebo-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression (anemia, leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Mucositis / stomatitis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infection (due to immunosuppression)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that inhibits the enzyme dihydrofolate reductase, which is essential for converting dihydrofolate to tetrahydrofolate in the one-carbon transfer pathway. This disruption reduces the synthesis of purines and pyrimidines, leading to decreased DNA and RNA synthesis. At lower doses used in rheumatologic conditions, it also has immunosuppressive and anti-inflammatory effects through adenosine release and inhibition of T-cell activation.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:17.508Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Various malignancies (acute leukemias, lymphomas, breast cancer)"}]},"trialDetails":[{"nctId":"NCT06578728","phase":"PHASE4","title":"Local Methotrexate Injections for the Treatment of Nail Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-09-10","conditions":"Nail Psoriasis","enrollment":1},{"nctId":"NCT07280156","phase":"PHASE2","title":"A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)","status":"RECRUITING","sponsor":"Protalix","startDate":"2025-12-22","conditions":"Gout","enrollment":150},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT04380740","phase":"PHASE2","title":"Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2022-03-30","conditions":"Graft Vs Host Disease","enrollment":160},{"nctId":"NCT07409103","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)","status":"NOT_YET_RECRUITING","sponsor":"Elevara Medicines Limited","startDate":"2026-01-31","conditions":"Active Rheumatoid Arthritis","enrollment":180},{"nctId":"NCT07171983","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-28","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT04196868","phase":"PHASE2","title":"Methotrexate and Metformin in Rheumatoid Arthritis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2020-12-03","conditions":"Arthritis, Rheumatoid","enrollment":128},{"nctId":"NCT05306353","phase":"PHASE2","title":"CD40L Antagonism in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-25","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT04237103","phase":"PHASE2","title":"Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2023-05-23","conditions":"Vitiligo","enrollment":32},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT01143337","phase":"PHASE2","title":"Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-06","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT04579848","phase":"PHASE4","title":"Methotrexate in Erosive Inflammatory Hand Osteoarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2021-08-12","conditions":"Hand Osteoarthritis, Erosive Osteoarthritis","enrollment":163},{"nctId":"NCT04483466","phase":"PHASE3","title":"Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"George Washington University","startDate":"2023-07-18","conditions":"Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity","enrollment":150},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT06590090","phase":"PHASE2","title":"Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment","status":"NOT_YET_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2026-07-15","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":"Ulcerative Colitis","enrollment":355},{"nctId":"NCT05166304","phase":"PHASE1, PHASE2","title":"Rebamipide in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"October 6 University","startDate":"2024-01-01","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT06671054","phase":"PHASE2","title":"A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2024-10-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":240},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT07161336","phase":"PHASE2","title":"Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-07-30","conditions":"Osteo Arthritis of the Knee, Synovitis of Knee, Methotrexate","enrollment":70},{"nctId":"NCT03775460","phase":"NA","title":"Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2023-01-15","conditions":"Erythema Nodosum Leprosum","enrollment":550},{"nctId":"NCT06239311","phase":"PHASE3","title":"Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.","status":"RECRUITING","sponsor":"medac GmbH","startDate":"2024-02-27","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":277},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":"Dermatomyositis","enrollment":62},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT04068246","phase":"PHASE1, PHASE2","title":"The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-08-01","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT06073093","phase":"PHASE2","title":"A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-07","conditions":"Rheumatoid Arthritis","enrollment":264},{"nctId":"NCT01554696","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-07-06","conditions":"Arthritis, Rheumatoid","enrollment":379},{"nctId":"NCT05533372","phase":"PHASE1","title":"MAD Study of IA-14069","status":"RECRUITING","sponsor":"ILAb Co., Ltd.","startDate":"2022-10-10","conditions":"Healthy, Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT05460832","phase":"PHASE2","title":"Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA","status":"COMPLETED","sponsor":"Modern Biosciences Ltd","startDate":"2022-08-29","conditions":"Rheumatoid Arthritis","enrollment":248},{"nctId":"NCT06281184","phase":"","title":"A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA.","status":"ENROLLING_BY_INVITATION","sponsor":"Diakonhjemmet Hospital","startDate":"2024-07-29","conditions":"Hand Osteoarthritis, Erosive Osteoarthritis","enrollment":108},{"nctId":"NCT06231745","phase":"PHASE3","title":"Paroxetine Safety and Efficacy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2024-01-31","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT06870500","phase":"NA","title":"Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient","status":"RECRUITING","sponsor":"South Valley University","startDate":"2025-03-05","conditions":"Psoriatic Arthritis","enrollment":50},{"nctId":"NCT01242917","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":159},{"nctId":"NCT05374785","phase":"PHASE2","title":"Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2022-05-01","conditions":"Rheumatoid Arthritis","enrollment":106},{"nctId":"NCT05363891","phase":"PHASE2","title":"Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"XBiotech, Inc.","startDate":"2023-08-08","conditions":"Rheumatoid Arthritis","enrollment":243},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT01451203","phase":"PHASE3","title":"Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-10-11","conditions":"Rheumatoid Arthritis","enrollment":319},{"nctId":"NCT06724952","phase":"PHASE4","title":"Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":44},{"nctId":"NCT01009242","phase":"PHASE1, PHASE2","title":"To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-10","conditions":"Arthritis, Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT05604885","phase":"PHASE2","title":"A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"SynAct Pharma Aps","startDate":"2022-11-30","conditions":"Rheumatoid Arthritis","enrollment":125},{"nctId":"NCT02698657","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-02-23","conditions":"Rheumatoid Arthritis (RA)","enrollment":30},{"nctId":"NCT03257852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-09-29","conditions":"Rheumatoid Arthritis (RA)","enrollment":66},{"nctId":"NCT02305849","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-07-25","conditions":"Rheumatoid Arthritis","enrollment":519},{"nctId":"NCT02884635","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-09-16","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":385},{"nctId":"NCT06641128","phase":"PHASE4","title":"The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-10-15","conditions":"Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse Reaction","enrollment":44},{"nctId":"NCT03016013","phase":"PHASE3","title":"A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2017-03-29","conditions":"Moderate and Severe RheumatoId Arthritis","enrollment":479},{"nctId":"NCT04170504","phase":"PHASE2, PHASE3","title":"Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-11-14","conditions":"Rheumatoid Arthritis","enrollment":204},{"nctId":"NCT05279417","phase":"PHASE2","title":"ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2022-02-01","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT01393639","phase":"PHASE2","title":"Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-27","conditions":"Rheumatoid Arthritis","enrollment":323},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT00847613","phase":"PHASE3","title":"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Arthritis, Rheumatoid","enrollment":800},{"nctId":"NCT02897700","phase":"PHASE1","title":"A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT05594680","phase":"PHASE3","title":"Cilostazol and Methotrexate in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2022-10-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT05623592","phase":"PHASE2","title":"Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bonn","startDate":"2022-11-23","conditions":"Giant Cell Arteritis","enrollment":52},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":3},{"nctId":"NCT03980483","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-05-16","conditions":"Arthritis, Rheumatoid","enrollment":1537},{"nctId":"NCT01751776","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-12-18","conditions":"Arthritis, Rheumatoid, Healthy","enrollment":107},{"nctId":"NCT03815448","phase":"NA","title":"Methotrexate in the Treatment of Advanced Knee Osteoarthritis With Effusion-synovitis","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2019-07-18","conditions":"Knee Osteoarthritis, Effusion Synovial, Knee Pain","enrollment":215},{"nctId":"NCT06277635","phase":"NA","title":"Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2024-02-01","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis","enrollment":72},{"nctId":"NCT03355482","phase":"PHASE2","title":"MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE","status":"TERMINATED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2017-04-10","conditions":"Systemic Lupus Erythematosus Arthritis","enrollment":9},{"nctId":"NCT05447520","phase":"PHASE2","title":"Montelukast Use in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Noha Mansour","startDate":"2021-12-15","conditions":"Rheumatoid Arthritis","enrollment":92},{"nctId":"NCT02706951","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-23","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02663622","phase":"PHASE2","title":"Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)","status":"COMPLETED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2016-09-19","conditions":"Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia","enrollment":44},{"nctId":"NCT05380934","phase":"PHASE1","title":"A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-05-29","conditions":"Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT03371667","phase":"PHASE3","title":"To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08-16","conditions":"Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute","enrollment":102},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT00579878","phase":"PHASE3","title":"Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-27","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT02760368","phase":"PHASE3","title":"Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-05-19","conditions":"Rheumatoid Arthritis","enrollment":428},{"nctId":"NCT02760433","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2017-01-25","conditions":"Rheumatoid Arthritis","enrollment":368},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT00280917","phase":"PHASE2","title":"Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Can-Fite BioPharma","startDate":"2006-06","conditions":"Rheumatoid Arthritis","enrollment":254},{"nctId":"NCT04046250","phase":"PHASE2","title":"Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690","status":"COMPLETED","sponsor":"Tosk, Inc.","startDate":"2019-05-15","conditions":"Mucositis","enrollment":22},{"nctId":"NCT02706873","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-23","conditions":"Rheumatoid Arthritis","enrollment":1002},{"nctId":"NCT02270632","phase":"PHASE2","title":"A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX","status":"TERMINATED","sponsor":"Philogen S.p.A.","startDate":"2014-10-01","conditions":"Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT03965728","phase":"PHASE1","title":"Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-06-05","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT00042406","phase":"PHASE2, PHASE3","title":"Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker","status":"TERMINATED","sponsor":"Genmab","startDate":"2002-03-04","conditions":"Rheumatoid Arthritis","enrollment":83},{"nctId":"NCT02772965","phase":"PHASE3","title":"Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-10","conditions":"Pediatric Crohn's Disease","enrollment":306},{"nctId":"NCT04341545","phase":"PHASE3","title":"Letrozole in Tubal Ectopic Pregnancy","status":"UNKNOWN","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2020-12-01","conditions":"Tubal Pregnancy","enrollment":214},{"nctId":"NCT04247815","phase":"PHASE2","title":"Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2020-03-16","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT04038970","phase":"PHASE2","title":"Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2019-11-08","conditions":"Rheumatoid Arthritis","enrollment":145},{"nctId":"NCT03813199","phase":"PHASE2","title":"Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-07-04","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04095858","phase":"PHASE3","title":"Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)","status":"TERMINATED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2021-01-05","conditions":"Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT02373813","phase":"PHASE3","title":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-20","conditions":"Rheumatoid Arthritis","enrollment":371},{"nctId":"NCT02440464","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT03589833","phase":"PHASE4","title":"Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-14","conditions":"Arthritis, Rheumatoid","enrollment":504},{"nctId":"NCT00883896","phase":"PHASE2","title":"Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06-18","conditions":"Rheumatoid Arthritis","enrollment":195},{"nctId":"NCT02376790","phase":"PHASE3","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-03-03","conditions":"Psoriatic Arthritis","enrollment":851},{"nctId":"NCT01773395","phase":"PHASE2","title":"GVAX vs. Placebo for MDS/AML After Allo HSCT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01-08","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":123},{"nctId":"NCT04577781","phase":"PHASE2","title":"A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2020-10-12","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT04227366","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-11-19","conditions":"Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT03522415","phase":"PHASE3","title":"Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2018-05-28","conditions":"Moderately to Severely Active Rheumatoid Arthritis","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intra-lesional","Sub-study"],"phase":"marketed","status":"active","brandName":"Placebo Methotrexate","genericName":"Placebo Methotrexate","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. Used for Rheumatoid arthritis, Psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}